SCHEMBL7417015

SCHEMBL7417015

NC(=O)c1cccc2c1c1[c]cccc1n2Cc1ccccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 7/20 0.41
KDM4E B2RXH2 3/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 1/20 0.40
NOD2 Q9HC29 1/20 0.40
LMNA P02545 3/20 0.40
TSHR P16473 2/20 0.39
KMT2A Q03164 1/20 0.38
AURKA O14965 1/20 0.38
RPS6KB1 P23443 1/20 0.38
FABP3 P05413 1/20 0.38
FABP4 P15090 1/20 0.38
MAPK8 P45983 1/20 0.37
DRD2 P14416 1/20 0.37
HTR6 P50406 1/20 0.37
HTT P42858 2/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PARP1 P09874 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27507603 0.91 FABP4 (0.40) ALDH1A1KDM4EKMT2AFABP4
SCHEMBL2590504 0.88 CA5A (0.38) L3MBTL1ALDH1A1KDM4ELMNAKMT2A
SCHEMBL27506428 0.88 AURKA (0.41) ALDH1A1KDM4EAURKARPS6KB1MAPK8
SCHEMBL27505654 0.88 MAPK8 (0.39) ALDH1A1KDM4EAURKARPS6KB1MAPK8
SCHEMBL27506841 0.88 ABCC1 (0.35) ALDH1A1KDM4EAURKARPS6KB1PARP1
SCHEMBL27506049 0.87 PLA2G2A (0.38) FABP4
SCHEMBL27568355 0.87 DGAT1 (0.41) KDM4EKMT2AHSD17B10
SCHEMBL27506350 0.87 CYP3A4 (0.33) LMNAAURKARPS6KB1
SCHEMBL27506849 0.87 CD38 (0.40) LMNAKMT2A
SCHEMBL27506439 0.87 L3MBTL1 (0.41) L3MBTL1ALDH1A1KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1259260-A1 COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES ELI LILLY AND COMPANY (US) 2002-11-27 EP claimed
WO-2001049323-A1 COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES ELI LILLY AND COMPANY (US) 2001-07-12 WO claimed
CN-102271507-A Secreted phospholipase A2(SPLA2) Inhibitor and niacin pharmaceutical composition and method for treating cardiovascular diseases and dyslipidemia 2011-12-07 CN disclosed
WO-2001055108-A2 USE OF SPL A2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION ELI LILLY AND COMPANY (US) 2001-08-02 WO disclosed
CN-1240210-A Substituted tricyclic compound LILLY CO ELI (US) 2000-01-05 CN disclosed